Nat. Rev. Clin. Oncol. doi: /nrclinonc

Slides:

Advertisements

Similar presentations

Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment Schafer ZT, Grassian AR, Song L, Jiang Z, Gerhart-Hines Z, Irie.

Advertisements

Cell Respiration Chapter 9. Slide 2 of 40 Cellular Respiration.

Energy for the body Trapped in chemical bonds of fats, proteins, and carbs (potential) liberate energy –break bonds –release energy, CO 2 and.

Center for the Study of Biological Complexity

Is Cancer a Metabolic Disease?

Electron Transport Chain

Energy Using Stage of Glycolysis

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Concept of the therapeutic index

Figure 3 Metabolism in homeostatic chondrocytes

Figure 2 Multiscale modelling in oncology

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 25.1 An Introduction to Cellular Metabolism

Figure 4 Autophagy and ischaemia–reperfusion

Figure 3 Monitoring clonal evolution using liquid biopsies

Metabolism The sum total of ALL chemical reactions within a cell

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Energy supply–demand matching in health and heart failure

Figure 3 The cell cycle and the role of CDK4/6 inhibition

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Immune cell metabolism during homeostasis

Figure 4 Possible combination therapies CDK4/6 inhibitors

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Metabolic configurations of M1 and M2 macrophages

A Mitochondrial Power Play in Lymphoma

Figure 2 Metabolic reprogramming of immune cells upon activation

Figure 1 Metabolic adaptations of cancer cells

Figure 5 Regulation of inflammation by metabolites

Figure 1 CAR-T-cell design

Figure 1 Cost of one month of treatment with

Figure 2 The association between CD8+ T‑cell density of the tumour

Figure 4 Altered metabolism in chondrocytes in osteoarthritis

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Drug cycling with collateral sensitivity

Figure 4 Road to targeting mutant p53

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Critical signalling pathways involved in PDAC pathogenesis

Figure 2 Metabolic heterogeneity in tumours

Figure 3 Summary of overall survival by Kaplan–Meier

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Figure 2 Median monthly launch price of a new anticancer drug,

Coming up for air: HIF-1 and mitochondrial oxygen consumption

Figure 1 Simplified representation of the physiological

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Understanding the Intersections between Metabolism and Cancer Biology

Figure 2 Dominance of the cell-extrinsic effects of autophagy

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Waste Not, Want Not: Lactate Oxidation Fuels the TCA Cycle

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Radiogenomics analysis can reveal relationships

Glycolytic and mitochondrial ATP production, the electron transport chain, and oxidative phosphorylation Glycolytic and mitochondrial ATP production, the.

Figure 1 Overview of the imaging biomarker roadmap

Power Surge: Supporting Cells “Fuel” Cancer Cell Mitochondria

MYC-regulated metabolic pathways in cancer.

Schematic depicting the Gcn5-regulated metabolic pathways.

Figure 1 Thyroid hormone effects on hepatic lipid metabolism

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Main metabolic pathways deregulated in cancers and corresponding targeting drugs. Main metabolic pathways deregulated in cancers and corresponding targeting.

Presentation transcript:

Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2016.60 Figure 3 Examples of existing and potential anticancer drugs that target metabolic processes Figure 3 | Examples of existing and potential anticancer drugs that target metabolic processes. Several pathways of the bioenergetic and anabolic metabolism of malignant cells harbour targets for the treatment of cancer. In general, agents that disrupt these pathways would be expected to result in deficiencies in energy and materials needed for cell proliferation and, potentially, survival, forming the basis for their use as anticancer therapies. For example, depletion of arginine or glutamate would be expected to cause metabolic collapse in cancer cells. Inhibiting ROS production, autophagy, or glycolysis in the catabolic compartment might also be an effective anticancer strategy. 2DG, 2-deoxyglucose; BP, bisphosphate (or bisphospho); BPTES, bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3; CoA, coenzyme A; DCA, dichloroacetate; GLUT1/GLUT4, glucose transporter 1/4; MCT1, monocarboxylate transporter 1; MCT4, monocarboxylate transporter 4; NAC, N-acetylcysteine; OXPHOS, oxidative phosphorylation; P, phosphate (or phospho); ROS, reactive oxygen species; TCA, tricarboxylic acid. Martinez-Outschoorn, U. E. et al. (2016) Cancer metabolism: a therapeutic perspective Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2016.60